$0.85
−0.05%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.84
From 52W high−73.66%
Volume36340.00
Market cap$4.20M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.84
From 52W high
−73.66%
Volume
36340.00
Market cap
$4.20M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
44.8
MomentumView details →
1D Return
−0.05%
YTD Return
−64.27%
SummaryUpdated Jun 1, 2026
Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. The company went public in August 2021 and focuses on developing pharmaceutical treatments for medical and aesthetic dermatological conditions. As a clinical-stage biotech firm, Dermata has no commercial products yet and is currently advancing multiple drug candidates through various phases of clinical trials, with its lead compound targeting common skin conditions like acne, psoriasis, and rosacea.
Similar companies
Latest newsMore news →
Dermata Therapeutics announced positive topline results from a cosmetic study of Tome Foundational Treatment, reporting improvements in skin appearance after four weekly treatments and overall skin improvement in more than 71% of participants after one treatment.20d agoDermata Therapeutics announced the commercial launch of its Tome Foundational Treatment skincare product, now available for purchase on its website.71d agoDermata Therapeutics announced the launch date of its first commercial product, Tome Foundational Treatment, expected on August 25, 2026.85d ago